Joshua Richter, MD

Articles

Dr. Richter on the Importance of Optimizing Available Therapies in Multiple Myeloma

September 2nd 2020

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

Dr. Richter on the Utility of Isatuximab in Relapsed/Refractory Myeloma

August 31st 2020

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Dr. Richter on Toxicities of Treatments for Multiple Myeloma

February 28th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

Dr. Richter on Findings of a Study on Symptom Management in Multiple Myeloma

February 3rd 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses the findings from a study on the incidence and survival impact of self-reported symptom and psychological distress for patients with multiple myeloma.

Dr. Richter on Study of Symptom Management in Multiple Myeloma

January 18th 2018

Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center discusses symptom management in patients with multiple myeloma.

Dr. Richter on Pomalidomide as Sickle Cell Disease Treatment

May 14th 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses using the FDA-approved multiple myeloma drug pomalidomide to treat patients with sickle cell disease.

Dr. Richter on Novel Oral Anticoagulants

April 21st 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the use of novel oral anticoagulants for use in patients with hematologic malignancies.

Dr. Richter Discusses the Administration of Carfilzomib

March 24th 2014

Joshua Richter, MD, hematologist/oncologist, multiple myeloma, John Theurer Cancer Center, discusses the administration of carfilzomib.

x